Observational studyEpilepsy & behavior : E&B2026
The role of Vagus nerve stimulation in epilepsy with eyelid myoclonia - A case series.
Observational study in Epilepsy & behavior : E&B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo study the effectiveness of vagus nerve stimulation (VNS) in patients with epilepsy with eyelid myoclonia (EEM, previously known as Jeavons Syndrome).
backgroundEEM is an epilepsy syndrome characterized by eyelid myoclonia, eyelid closure-induced generalized EEG paroxysms or seizures, and photosensitivity. Many patients have drug-resistant epilepsy; however, the effectiveness of VNS in this epilepsy syndrome has not been well studied.
methodsThis is a single institution retrospective observational study of patients with EEM. Among a database of 134 patients with EEM, we identified those treated with VNS. Epilepsy history, VNS parameters, and response to VNS were abstracted.
resultsWe identified 12 patients who were treated with VNS (50% female). The median age of epilepsy onset was 5 (range 4-14) years; age of VNS implantation was 16 (range 6-33) years, and median duration of VNS treatment was 13.5 (range 0-24) years. Four patients (33.3%) were responders reporting greater than 50% improvement in seizure frequency. All four patients (33.3%) showed response with generalized tonic-clonic seizures, myoclonic seizures, and three patients (25%) reported response with eyelid myoclonia and absence seizures. One patient had the VNS explanted due to lack of efficacy and one had it turned off for enrollment in a clinical trial. The median maximum tolerated output current settings for our cohort were 1.75 mA (IQR 1.38-1.94; range 0.75-2.25) with an OFF time of 1.8 min (IQR 1.1-3, range 0.2-3) and median duty cycle of 24% (IQR 16-29; range 12-58).
conclusionsFrom this small case series of patients with EEM, four (33.3%) were responders to VNS, with improvement noted in multiple seizure types. This indicates the potential role of VNS for patients with EEM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.